Article
Hematology
Simon J. Harrison, Aurore Perrot, Adrian Alegre, David Simpson, Ming Chung Wang, Andrew Spencer, Sosana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Facon, Philip Vlummens, Kwee Yong, Frank Campana, Marlene Inchauspe, Sandrine Mace, Marie-Laure Risse, Helgi Velde, Paul Richardson
Summary: The ICARIA-MM trial demonstrated that isatuximab plus pomalidomide-dexamethasone provides consistent benefits in terms of improving progression-free survival and overall response rate in both high-risk and patients with gain(1q21) abnormality. Despite higher rates of grade >= 3 adverse events, isatuximab did not increase treatment discontinuation or mortality events in high-risk patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis-Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Kyriaki Manousou, Sosana Delimpasi, Panagiotis Malandrakis, Marie-Christine Kyrtsonis, Maria Papaioannou, Argiris Symeonidis, Meletios-Athanasios Dimopoulos
Summary: The study demonstrates that the anti-CD38 monoclonal antibody daratumumab improves bone turnover in patients with multiple myeloma by inducing bone formation and reducing osteoblast inhibition, highlighting its clinical significance.
Article
Oncology
Uros Markovic, Alessandra Romano, Vittorio Del Fabro, Claudia Bellofiore, Anna Bulla, Marina Silvia Parisi, Salvatore Leotta, Massimo Gentile, Clotilde Cangialosi, Iolanda Vincelli, Giuseppe Mineo, Marco Rossi, Massimo Poidomani, Giuseppina Uccello, Cinzia Maugeri, Donato Mannina, Vanessa Innao, Francesco Di Raimondo, Concetta Conticello
Summary: The study shows that daratumumab as a single agent is a safe and well-tolerated regimen in real-life, associated with prolonged progression free survival and overall survival in responding patients. No new safety signals were identified.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Dario Roccatello, Roberta Fenoglio, Ilaria Caniggia, Joelle Kamgaing, Carla Naretto, Irene Cecchi, Elena Rubini, Daniela Rossi, Emanuele De Simone, Giulio Del Vecchio, Martina Cozzi, Savino Sciascia
Summary: This study presents a case series of six patients with refractory lupus nephritis who were treated with an off-label anti-CD38 monoclonal antibody. Five patients achieved complete or partial renal responses after 12 months of follow-up. These findings suggest that daratumumab monotherapy shows promise as a potential treatment for refractory lupus nephritis.
Article
Oncology
Ja Min Byun, Chang-Ki Min, Kihyun Kim, Soo-Mee Bang, Je-Jung Lee, Jin Seok Kim, Sung-Soo Yoon, Youngil Koh
Summary: Extramedullary multiple myeloma (EMD) is a subentity of multiple myeloma (MM) with poor prognosis. This study evaluated the efficacy and safety of daratumumab in combination with multiple drugs for the treatment of EMD. The results showed that the complete remission rate was 35.5% and overall response rate was 67.7%. Long-term responders had a significantly improved progression-free survival. The most common adverse events were hematologic and non-hematologic toxicities.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Hematology
Sung-Soo Park, Ja Min Byun, Sung-Soo Yoon, Kihyun Kim, Sung-Hoon Jung, Je-Jung Lee, Chang-Ki Min
Summary: Real-world outcomes of daratumumab monotherapy for relapsed/refractory multiple myeloma showed favorable responses, but certain factors related to trial-unfitness may offset its efficacy. Patients in the modified trial-unfit group had poorer survival outcomes, indicating the potential impact of specific characteristics on treatment efficacy.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Massimo Offidani, Laura Corvatta, Sonia More, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione
Summary: Immunotherapy with daratumumab has been approved for the treatment of multiple myeloma and has shown significant efficacy in both relapsed-refractory and newly diagnosed patients, utilizing various mechanisms of action to target CD38. Ongoing trials are exploring new combinations with daratumumab to provide further insights into its potential benefits for MM patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Kristine A. Frerichs, Monique C. Minnema, Mark-David Levin, Annemiek Broijl, Gerard M. J. Bos, Marie Jose Kersten, Tuna Mutis, Christie P. M. Verkleij, Inger S. Nijhof, Patricia W. C. Maas-Bosman, Saskia K. Klein, Sonja Zweegman, Pieter Sonneveld, Niels W. C. J. van de Donk
Summary: This study evaluated the efficacy and safety of daratumumab combined with all-trans retinoic acid (ATRA) in patients with daratumumab-refractory multiple myeloma (MM). The findings suggest limited activity of the combination in reversing daratumumab resistance, possibly due to transient upregulation of CD38 expression.
Article
Hematology
Xiao Hu, Cherng-Horng Wu, Janet M. Cowan, Raymond L. Comenzo, Cindy Varga
Summary: Chromosome 1q gain/amplification has been linked to poor outcomes in multiple myeloma patients, and the introduction of monoclonal antibodies has changed treatment options. Limited data is available regarding outcomes in patients with 1q + in the era of monoclonal antibodies. Studying newly diagnosed MM patients revealed that elevated LDH levels were associated with shorter overall survival, while higher bone marrow plasma cell percentage was linked to worse progression-free survival. Presence of 1q + copy number more than three correlated with shorter overall survival and progression-free survival. The use of lenalidomide showed superior overall survival, while autologous stem cell transplantation, bortezomib, and daratumumab did not provide prognostic benefits in this specific population. More research is needed to confirm the benefits of lenalidomide and explore the role of monoclonal antibodies further in this subpopulation.
ANNALS OF HEMATOLOGY
(2022)
Review
Oncology
Jose-angel Hernandez-Rivas, Rafael Rios-Tamayo, Cristina Encinas, Rafael Alonso, Juan-Jose Lahuerta
Summary: The increase in therapeutic alternatives for multiple myeloma patients has made the clinical scenario more complex. The choice of previously unused drugs and previous therapeutic regimens have a greater impact on treatment efficacy than the characteristics of the disease itself. New generation drugs have been developed to fight relapsed/refractory multiple myeloma.
BIOMARKER RESEARCH
(2022)
Article
Oncology
Evangelos Terpos, Kimon Stamatelopoulos, Nikolaos Makris, Georgios Georgiopoulos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Ageliki Laina, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Nikolaos Kanellias, Panagiotis Malandrakis, Dimitris Delialis, Ioanna Andreadou, Efstathios Kastritis, Meletios A. Dimopoulos
Summary: The study evaluated the potential cardioprotective effect of daratumumab when administered in combination with carfilzomib and dexamethasone, showing preserved post-treatment cardiac systolic function and lower cardiovascular adverse event rate. Further investigation is needed to determine the clinical significance and underlying mechanisms.
Review
Hematology
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari
Summary: Daratumumab is a human immunoglobulin G1 kappa monoclonal antibody that targets CD38 and has been approved for use in both newly diagnosed and relapsed refractory multiple myeloma. The subcutaneous formulation of daratumumab has shorter administration time, lower rates of infusion-related reactions, and smaller infusion volume compared to the intravenous formulation. Despite these differences, the pharmacokinetics, safety profile, and efficacy are comparable between the two formulations.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Article
Hematology
Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Tomas Jelinek, Alexandra Jungova, Petr Pavlicek, Lenka Pospisilova, Frantisek Sedlak, Jan Straub, Tomas Pika, Zdenka Knechtova, Anna Fidrichova, Ivanna Boichuk, Sabina Sevcikova, Vladimir Maisnar, Roman Hajek, Ludek Pour
Summary: We conducted a real-world evidence (RWE) analysis comparing the treatment of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) to lenalidomide and dexamethasone (Rd) in relapsed/refractory multiple myeloma patients (RRMM). Our analysis included 240 RRMM patients treated with Dara-Rd and 531 RRMM patients treated with Rd as a reference. The results showed that Dara-Rd achieved a significantly higher partial response or better response rate (91.2% vs. 69.9%) and longer median progression-free survival (26.9 months vs. 12.8 months) compared to Rd. In heavily pretreated RRMM patients, the efficacy of Dara-Rd treatment was limited, with the best outcomes observed in minimally pretreated patients.
ANNALS OF HEMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Anne-Gaelle Dosne, Xia Li, Man Melody Luo, Ivo Nnane, Meletios A. Dimopoulos, Evangelos Terpos, Pieter Sonneveld, Tobias Kampfenkel, Robin Carson, Himal Amin, Juan Perez Ruixo, Honghui Zhou, Yu-Nien Sun, Yan Xu
Summary: A PPK model was developed to characterize the pharmacokinetics of daratumumab in patients with RRMM. The analysis revealed a relationship between daratumumab exposure and efficacy and safety. The study supports the use of subcutaneous administration of daratumumab at a dose of 1800 mg in combination with Pd for the treatment of RRMM patients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Oncology
Kristine A. Frerichs, Christie P. M. Verkleij, Meletios A. Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W. C. J. van de Donk
Summary: Daratumumab, a CD38-targeting antibody, shows significant activity in multiple myeloma but resistance often develops. The addition of the PD-L1 checkpoint inhibitor durvalumab at the time of daratumumab failure did not reverse daratumumab-resistance. This suggests that PD-L1 co-targeting may not be sufficient to overcome daratumumab-resistance.
Letter
Oncology
Meera Mohan, Sneha Nagavally, Nirav N. N. Shah, Laura Michaelis, Saurabh Chhabra, Anita D. Souza, Sameem Abedin, Lyndsey Runaas, Walter Longo, Mehdi Hamadani, Binod Dhakal, Parameswaran Hari, Timothy S. Fenske
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Letter
Hematology
Meera Mohan, Sneha Nagavally, Binod Dhakal, Sabarinath Venniyil Radhakrishnan, Saurabh Chhabra, Anita D'Souza, Parameswaran Hari
Article
Hematology
Meera Mohan, Samantha Kendrick, Aniko Szabo, Naveen Yarlagadda, Dinesh Atwal, Yadav Pandey, Arya Roy, Richa Parikh, James Lopez, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Jeffrey Sawyer, Erming Tian, Guido Tricot, Frits van Rhee, Maurizio Zangari
Summary: In multiple myeloma patients, achieving bone marrow minimal residual disease negativity following treatment can predict the risk of relapse. Monitoring MRD conversion through flow cytometry may be a valuable tool in identifying patients at high risk of relapse, particularly within the first five years post-treatment. Early detection of MRD conversion can aid in making informed decisions regarding salvage therapy to prevent clinical relapse.
Letter
Hematology
Meera Mohan, Sravani Gundarlapalli, Aniko Szabo, Naveen Yarlagadda, Sunilkumar Kakadia, Manojna Konda, Anusha Jillella, Amisha Fnu, Yetunde Ogunsesan, Lakshmi Yarlagadda, Nishant Thalambedu, Hussain Munawar, Monica Graziutti, Samer Al Hadidi, Daisy Alapat, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Carolina Schinke
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Letter
Hematology
Meera Mohan, Melody Renee Becnel, Urvi A. Shah, Huaying Dong, Sravani Gundarlapalli, Timothy Peterson, Jennifer S. Orozco, Sandra Horowitz, Saurabh Chhabra, Binod Dhakal, Sharmilan Thanendrarajan, Sabarinath Venniyil Radhakrishnan, Samer Al Hadidi, Carlyn Tan, Sham Mailankody, Malin Hultcrantz, Neha Korde, Hani Hassoun, Alexander M. Lesokhin, Sheeba K. Thomas, Krina K. Patel, Elisabet E. Manasanch, Donna M. Weber, Aniko Szabo, Gregory P. Kaufman, Hans C. Lee, Maurizio Zangari, Frits van Rhee, Saad Z. Usmani, Anita D'Souza, Robert Z. Orlowski, Carolina Schinke
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Oncology
Jing Dong, Zhuping Garacci, Christopher Staffi Buradagunta, Anita D'Souza, Meera Mohan, Ashley Cunningham, Siegfried Janz, Binod Dhakal, Aaron P. Thrift, Parameswaran Hari
Summary: This study assessed the survival differences between non-Hispanic black (NHB) and non-Hispanic white (NHW) patients with multiple myeloma (MM), and found that equitable access to effective treatment modalities is crucial in improving the survival of NHB patients.
BLOOD CANCER JOURNAL
(2022)
Letter
Hematology
Ariel Kleman, Arun Singavi, Lauren Pommert, Angela J. Mathison, Parameswaran Hari, Binod Dhakal, Meera Mohan, Siegfried Janz, Jennifer M. Knight, Mithun Shah, Carolina Schinke, Robert Burns, George Francis Steinhardt, Sridhar Rao, Karen Carlson
Letter
Biophysics
Meera Mohan, Siegfried Janz, Ruta Brazauskas, Michael B. Dwinell, Bi Qing Teng, Grant Yun, Jing Dong, Marcelo C. Pasquini, Sergio Giralt, Heather Landau, Edward Stadtmauer, Amrita Krishnan, Anita D'Souza
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Meera Mohan, Rajshekhar Chakraborty, Susan Bal, Anoma Nellore, Muhamed Baljevic, Anita D'Souza, Peter G. Pappas, Jesus G. Berdeja, Natalie Callander, Luciano J. Costa
Summary: CAR T-cell and bispecific antibody therapies have shown remarkable efficacy in multiple myeloma patients, but they come with a significant risk of severe infections due to various factors. As these therapies have been recently approved, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from clinical trials become available. A panel of experienced investigators from COMMIT developed consensus recommendations for mitigating infections associated with CAR T-cell and bispecific antibody therapies in multiple myeloma patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Meera Mohan, Zimu Gong, Timothy Cody Ashby, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, John D. D. Shaughnessy Jr, Fenghuang Zhan, Frits van Rhee, Jeffery R. Sawyer, Erming Tian, Maurizio Zangari
Summary: Chromosome 1 abnormalities in multiple myeloma are recognized as high-risk features. This study reports the prognostic value of del(1p13.3) in patients treated on total therapy clinical trials. The presence of del(1p13.3) with 1q21 gain or amp predicts poor clinical outcomes.
Article
Hematology
Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, Wei Cui, Leyla Shune, Joseph McGuirk, Meera Mohan, Ghulam Rehman Mohyuddin, Aimaz Afrough, Omar Alkharabsheh, Shebli Atrash
Summary: This study analyzes the clinical efficacy of daratumumab retreatment in patients with daratumumab-refractory multiple myeloma, and suggests that combination therapy of daratumumab with other anti-myeloma drugs can generate responses in these patients.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Letter
Biophysics
Meera Mohan, Anai Kothari, Nathaniel Verhagen, Aditya Shreenivas, Sabarinath Venniyil Radhakrishnan, Binod Dhakal, Carlos Figueroa-Castro, Saurabh Chhabra, Siegfried Janz, Marcello Pasquini, Mehdi Hamadani, Aniko Szabo, Anita D'Souza
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Lindsay Hammons, Shabi Haider, Andrew J. Portuguese, Rahul Banerjee, Aniko Szabo, Marcelo Pasquini, Saurabh Chhabra, Sabarinath Radhakrishnan, Meera Mohan, Ravi Narra, Jing Dong, Siegfried Janz, Nirav N. Shah, Mehdi Hamadani, Anita D'Souza, Parameswaran Hari, Binod Dhakal
Summary: CAR-T and BsAb therapies are feasible, safe, and provide deep and durable responses in MM patients with a prior history of allo-HCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Oncology
Rajshekhar Chakraborty, Divaya Bhutani, Mathew S. Maurer, Meera Mohan, Suzanne Lentzsch, Anita D'Souza
BLOOD CANCER JOURNAL
(2023)
Meeting Abstract
Oncology
Aala Dweik, Hadeel Dweik, Hira Mian, Meera Mohan, Carolina D. Schinke, Samer Al Hadidi
JOURNAL OF CLINICAL ONCOLOGY
(2022)